The DOI matches its Crossref record; 185 of the 185 references it cites were found in a registry or an index.
Pharmacologic resistance in colorectal cancer: a review
Open accessAbstract
Colorectal cancer (CRC) persists as one of the most prevalent and deadly tumor types in both men and women worldwide. This is in spite of widespread, effective measures of preventive screening, and also major advances in treatment options. Despite advances in cytotoxic and targeted therapy, resistance to chemotherapy remains one of the greatest challenges in long-term management of incurable metastatic disease and eventually contributes to death as tumors accumulate means of evading treatment. We performed a comprehensive literature search on the data available through PubMed, Medline, Scopus, and the ASCO Annual Symposium abstracts through June 2015 for the purpose of this review. We discuss the current state of knowledge of clinically relevant mechanisms of resistance to cytotoxic and targeted therapies now in use for the treatment of CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332 · cited 1×
“TS expression is a key predictor of 5-FU activity [Longley et al. 2003], and its expression has long been recognized as a primary determinant of resistance [Berger et al.”
BackgroundSignet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature
Park, P. Y., Goldin, T., Chang, J., Markman, M., & Kundranda, M. N. (2015) · Case Reports in Oncology · doi:10.1159/000441772 · Cited by 5,273
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · cited 2×
“These function to promote vascular growth by producing cytokines, growth factors and proteases that promote vascular growth and development [Bergers and Hanahan, 2008].”
BackgroundTournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915 · cited 1×
“Numerous gene polymorphisms of OPRT, MTHFR, UGT1A1, and DPD have been investigated in relation to toxicity [Tsunoda et al. 2011; Choi et al. 2012], but to date none of these have demonstrated clinical significance in relation to chemoresistance.”
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895 · cited 2×
“The study also demonstrated an improvement in PFS, though there was no difference in overall response rate [Grothey et al. 2013].”
BackgroundResultEpidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Colorectal cancer statistics, 2014
Siegel, R., DeSantis, C., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21220 · Cited by 2,562
Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine
Sakuramoto, S., Sasako, M., Yamaguchi, T., Kinoshita, T., Fujii, M., Nashimoto, A., Furukawa, H., Nakajima, T., Ohashi, Y., Imamura, H., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072252 · Cited by 2,517
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 1×
“Resistance to EGFR antagonists is also influenced by neuronal RAS (NRAS) mutations [Douillard et al. 2013; Meriggi et al. 2014].”
BackgroundLevamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma
Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Goodman, P. J., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002083220602 · Cited by 2,256
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Cetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
Douillard, J.-Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4860 · Cited by 1,809
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Abdalla, E. K., Vauthey, J.-N., Ellis, L. M., Ellis, V., Pollock, R., Broglio, K. R., Hess, K., & Curley, S. A. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000128305.90650.71 · Cited by 1,750
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
ERK1/2 MAP kinases: Structure, function, and regulation
Roskoski, R. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.04.005 · Cited by 1,650
The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling
Lowenstein, E. J., Daly, R. J., Batzer, A. G., Li, W., Margolis, B., Lammers, R., Ullrich, A., Skolnik, E. Y., Bar-Sagi, D., & Schlessinger, J. (1992) · Cell · doi:10.1016/0092-8674(92)90167-b · Cited by 1,631
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Fluorinated pyrimidines, a new class of tumour-inhibitory compounds
HEIDELBERGER, C., CHAUDHURI, N. K., DANNEBERG, P., MOOREN, D., GRIESBACH, L., DUSCHINSKY, R., SCHNITZER, R. J., PLEVEN, E., & SCHEINER, J. (1957) · Nature · doi:10.1038/179663a0 · Cited by 1,603
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Cetuximab in the treatment of colorectal cancer.
Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518
Adam, R., Delvart, V., Pascal, G., Valeanu, A., Castaing, D., Azoulay, D., Giacchetti, S., Paule, B., Kunstlinger, F., Ghémard, O., et al. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000141198.92114.f6 · Cited by 1,480
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414325 · Cited by 1,431
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Van Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausová, J., Macarulla, T., Ruff, P., van Hazel, G. A., Moiseyenko, V., Ferry, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8201 · Cited by 1,402
The ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,353
De Palma, M., Venneri, M. A., Galli, R., Sergi, L. S., Politi, L. S., Sampaolesi, M., & Naldini, L. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.002 · Cited by 1,311
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Bennouna, J., Sastre, J., Arnold, D., Österlund, P., Greil, R., Van Cutsem, E., von Moos, R., Viéitez, J. M., Bouché, O., Borg, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70477-1 · Cited by 1,166 · cited 2×
“The results of this trial indicate that VEGF receptor blockade after progression through alternate angiogenesis blockade provides additional benefit, similar to what was seen in the TLM trial with bevacizumab [Bennouna et al. 2013] and the VELOUR trial with aflibercept [Tabernero et al.”
BackgroundResultAllegra, C. J., Jessup, J. M., Somerfield, M. R., Hamilton, S. R., Hammond, E. H., Hayes, D. F., McAllister, P. K., Morton, R. F., & Schilsky, R. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9170 · Cited by 1,156
Yang, L., DeBusk, L. M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., Matrisian, L. M., Carbone, D. P., & Lin, P. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.031 · Cited by 1,140
Hoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
Du, R., Lu, K. V., Petritsch, C., Liu, P., Ganss, R., Passegué, E., Song, H., VandenBerg, S., Johnson, R. S., Werb, Z., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.034 · Cited by 1,130
Maxwell, P. H., Dachs, G. U., Gleadle, J. M., Nicholls, L. G., Harris, A. L., Stratford, I. J., Hankinson, O., Pugh, C. W., & Ratcliffe, P. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.15.8104 · Cited by 1,084
Van Cutsem, E., Twelves, C., Cassidy, J., Allman, D., Bajetta, E., Boyer, M., Bugat, R., Findlay, M., Frings, S., Jahn, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.21.4097 · Cited by 1,032
Adam, R., Pascal, G., Castaing, D., Azoulay, D., Delvart, V., Paule, B., Levi, F., & Bismuth, H. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000145964.08365.01 · Cited by 1,001
Rougier, P., Van Cutsem, E., Bajetta, E., Niederle, N., Possinger, K., Labianca, R., Navarro, M., Morant, R., Bleiberg, H., Wils, J., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03085-2 · Cited by 992
Mechanisms of adverse effects of anti-VEGF therapy for cancer
Kamba, T., & McDonald, D. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603813 · Cited by 990
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis
Ridgway, J., Zhang, G., Wu, Y., Stawicki, S., Liang, W.-C., Chanthery, Y., Kowalski, J., Watts, R. J., Callahan, C., Kasman, I., et al. (2006) · Nature · doi:10.1038/nature05313 · Cited by 986 · cited 1×
“2007], and delta-like ligand-4 (Dll4) [Ridgway et al. 2006].”
Tabernero, J., Yoshino, T., Cohn, A. L., Obermannova, R., Bodoky, G., Garcia-Carbonero, R., Ciuleanu, T.-E., Portnoy, D. C., Van Cutsem, E., Grothey, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70127-0 · Cited by 952
Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70102-9 · Cited by 941
Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939 · cited 1×
“Amplification of HER2 has been noted in only 2–3% of untreated tumors, however has been shown that cetuximab-resistant cell lines demonstrate both HER2 amplification as well as an increase in secretion of heregulin, a ligand which binds to the HER2 receptor [Yonesaka et al. 2011; Ciardiello and Normanno, 2011; Bertott…”
BackgroundThomas, H., & Coley, H. M. (2003) · Cancer Control · doi:10.1177/107327480301000207 · Cited by 931
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849
Salonga, D. S., Danenberg, K. D., Johnson, M. R., Metzger, R., Groshen, S. G., Tsao-Wei, D. D., Lenz, H.-J., Leichman, C. G., Leichman, L., Diasio, R. B., et al. (2000) · PubMed · Cited by 829
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
Mancuso, M. R., Davis, R., Norberg, S. M., O'Brien, S., Sennino, B., Nakahara, T., Yao, V. J., Inai, T., Brooks, P., Freimark, B., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24612 · Cited by 809
Colucci, G., Gebbia, V., Paoletti, G., Giuliani, F., Caruso, M., Gebbia, N., Cartenì, G., Agostara, B., Pezzella, G., Manzione, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.113 · Cited by 779
Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Bardelli, A., & Siena, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.6116 · Cited by 746
Johnston, P. G., Lenz, H.-J., Leichman, C. G., Danenberg, K. D., Allegra, C. J., Danenberg, P. V., & Leichman, L. (1995) · PubMed · Cited by 672
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0558 · Cited by 657
Hattori, K., Heissig, B., Wu, Y., Dias, S., Tejada, R., Ferris, B., Hicklin, D. J., Zhu, Z., Bohlen, P., Witte, L., et al. (2002) · Nature Medicine · doi:10.1038/nm740 · Cited by 633
Crawford, Y., Kasman, I., Yu, L., Zhong, C., Wu, X., Modrusan, Z., Kaminker, J., & Ferrara, N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.004 · Cited by 611
Shirota, Y., Stoehlmacher, J., Brabender, J., Xiong, Y.-P., Uetake, H., Danenberg, K. D., Groshen, S., Tsao-Wei, D. D., Danenberg, P. V., & Lenz, H.-J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.23.4298 · Cited by 610
Cellular and molecular pharmacology of oxaliplatin.
Raymond, É., Faivre, S. J., Chaney, S. G., WOYNAROWSKI, J. M., & Cvitkovic, E. (2002) · PubMed · Cited by 576
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
Frattini, M., Saletti, P., Romagnani, E., Martin, V, Molinari, F., Ghisletta, M., Camponovo, A., Etienne, L. L., Cavalli, F., & Mazzucchelli, L. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604009 · Cited by 540
Ishikawa, T., & Ali-Osman, F. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80702-9 · Cited by 533
Blocking Neuropilin-1 Function Has an Additive Effect with Anti-VEGF to Inhibit Tumor Growth
Pan, Q., Chanthery, Y., Liang, W.-C., Stawicki, S., Mak, J., Rathore, N., Tong, R. K., Kowalski, J., Yee, S. F., Pacheco, G., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.10.018 · Cited by 532
Resistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution
Misale, S., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S., & Bardelli, A. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0462 · Cited by 513
Rubenstein, J. L., Kim, J., Ozawa, T., Zhang, M., Westphal, M., Deen, D. F., & Shuman, M. A. (2000) · Neoplasia · doi:10.1038/sj.neo.7900102 · Cited by 509
Kopetz, S., Hoff, P. M., Morris, J. S., Wolff, R. A., Eng, C., Glover, K. Y., Adinin, R., Overman, M. J., Valero, V., Wen, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.8252 · Cited by 485
Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis
Yamada, K. M., & Araki, M. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.13.2375 · Cited by 479
Leichman, C. G., Lenz, H. J., Leichman, L., Danenberg, K., Baranda, J., Groshen, S., Boswell, W., Metzger, R., Tan, M., & Danenberg, P. V. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.10.3223 · Cited by 475
Price, T. J., Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. S., Thomas, A., Tjulandin, S., Zhang, K., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70118-4 · Cited by 473
Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer
Carethers, J. M., Smith, E. J., Behling, C. A., Nguyen, L., Tajima, A., Doctolero, R. T., Cabrera, B. L., Goel, A., Arnold, C. A., Miyai, K., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.12.023 · Cited by 471
Van Cutsem, E., Labianca, R., Bodoky, G., Barone, C., Aranda, E., Nordlinger, B., Topham, C., Tabernero, J., André, T., Sobrero, A. F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6663 · Cited by 467
The role of DNA mismatch repair in drug resistance
Nebel, S. (1998) · ETH Zürich Research Collection · doi:10.3929/ethz-a-001915508 · Cited by 461
Jhawer, M., Goel, S., Wilson, A. J., Montagna, C., Ling, Y.-H., Byun, D.-S., Nasser, S., Arango, D., Shin, J., Klampfer, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5659 · Cited by 460
Popat, S., Matakidou, A., & Houlston, R. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.064 · Cited by 449
The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents
Tabernero, J. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0404 · Cited by 437
Organic Cation Transporters Are Determinants of Oxaliplatin Cytotoxicity
Zhang, S., Lovejoy, K. S., Shima, J. E., Lagpacan, L. L., Shu, Y., Lapuk, A., Chen, Y., Komori, T., Gray, J. W., Chen, X., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0769 · Cited by 431
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.
Xu, Y., & Villalona-Calero, M. A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf337 · Cited by 413
Mayer, A., Takimoto, M., Fritz, E., Schellander, G., Kofler, K., & Ludwig, H. (1993) · Cancer · doi:10.1002/1097-0142(19930415)71:8<2454::aid-cncr2820710805>3.0.co;2-2 · Cited by 412
Perrone, F., Lampis, A., Orsenigo, M., Di Bartolomeo, M., Gevorgyan, A., Losa, M., Frattini, M., Riva, C., Andreola, S., Bajetta, E., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn541 · Cited by 410
The role of DNA mismatch repair in drug resistance.
Fink, D. A., Aebi, S. P., & Howell, S. B. (1998) · PubMed · Cited by 410
Induction of interleukin-8 preserves the angiogenic response in HIF-1α–deficient colon cancer cells
Mizukami, Y., Jo, W.-S., Duerr, E.-M., Gala, M., Li, J., Zhang, X., Zimmer, M. A., Iliopoulos, O., Zukerberg, L. R., Kohgo, Y., et al. (2005) · Nature Medicine · doi:10.1038/nm1294 · Cited by 406
Therkildsen, C., Bergmann, T. K., Henrichsen-Schnack, T., Ladelund, S., & Nilbert, M. (2014) · Acta Oncologica · doi:10.3109/0284186x.2014.895036 · Cited by 390
Standing the test of time: targeting thymidylate biosynthesis in cancer therapy
Wilson, P. M., Danenberg, P. V., Johnston, P. G., Lenz, H.-J., & Ladner, R. D. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.51 · Cited by 388
Ciardiello, F., Bianco, R., Damiano, V., Fontanini, G., Caputo, R., Pomatico, G., Placido, S. D., Bianco, A. R., Mendelsohn, J. M., & Tortora, G. (2000) · PubMed · Cited by 378
Leichman, C. G., Fleming, T. R., Muggia, F. M., Tangen, C. M., Ardalan, B., Doroshow, J. H., Meyers, F. J., Holcombe, R. F., Weiss, G. R., & Mangalik, A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.6.1303 · Cited by 359
Sartore-Bianchi, A., Moroni, M., Veronese, S., Carnaghi, C., Bajetta, E., Luppi, G., Sobrero, A., Barone, C., Cascinu, S., Colucci, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5956 · Cited by 333
Yoshino, T., Mizunuma, N., Yamazaki, K., Nishina, T., Komatsu, Y., Baba, H., Tsuji, A., Yamaguchi, K., Muro, K., Sugimoto, N., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70345-5 · Cited by 326
Holzer, A. K., Manorek, G. H., & Howell, S. B. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.022624 · Cited by 322
Somatic Mutations of EGFR in Colorectal Cancers and Glioblastomas
Barber, T. D., Vogelstein, B., Kinzler, K. W., & Velculescu, V. E. (2004) · New England Journal of Medicine · doi:10.1056/nejm200412303512724 · Cited by 315
UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer
Marcuello, E., Altés, A., Menoyo, A., del Rio, E., Gómez-Pardo, M., & Baiget, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602042 · Cited by 315
Genetic Variability in CYP3A5 and its Possible Consequences
Xie, H.-G., Wood, A. J., Kim, R. B., Stein, C. M., & Wilkinson, G. R. (2004) · Pharmacogenomics · doi:10.1517/phgs.5.3.243.29833 · Cited by 302
Bécouarn, Y., Ychou, M., Ducreux, M., Borel, C., Bertheault-Cvitkovic, F., Seitz, J. F., Nasca, S., Nguyen, T. D., Paillot, B., Raoul, J. L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2739 · Cited by 301
Feng, J., Tamaskovic, R., Yang, Z., Brazil, D. P., Merlo, A., Hess, D., & Hemmings, B. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404936200 · Cited by 294
In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair.
Fink, D. A., Zheng, H., Nebel, S., Norris, P. S., Aebi, S. P., Lin, T., Nehmé, A., Christen, R. D., Haas, M., MacLeod, C. L., et al. (1997) · PubMed · Cited by 277
Relevance of Different UGT1A1 Polymorphisms in Irinotecan-Induced Toxicity
Rouits, E., Boisdron-Celle, M., Dumont, A., Guérin, O., Morel, A., & Gamelin, E. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0548 · Cited by 276
Meyers, M., Wagner, M. W., Hwang, H. S., Kinsella, T. J., & Boothman, D. A. (2001) · PubMed · Cited by 269
Cappuzzo, F., Finocchiaro, G., Rossi, E., Jänne, P. A., Carnaghi, C., Calandri, C., Bencardino, K., Ligorio, C., Ciardiello, F., Pressiani, T., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm492 · Cited by 267 · cited 1×
“Although the relationship between EGFR mutations and response remains unclear, there is evidence that increased copy number of the EGFR receptor, as measured by fluorescent in situ hybridization (FISH), is a positive predictor of response to treatment with both cetuximab and panitumumab [Sartore-Bianchi et al. 2007; C…”
BackgroundCarlini, L. E., Meropol, N. J., Bever, J., Andria, M. L., Hill, T., Gold, P., Rogatko, A., Wang, H., & Blanchard, R. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.1226.11.3 · Cited by 262
Sartore-Bianchi, A., Di Nicolantonio, F., Nichelatti, M., Molinari, F., De Dosso, S., Saletti, P., Martini, M., Cipani, T., Marrapese, G., Mazzucchelli, L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007287 · Cited by 259
EGF, TGF-a, and EGF-R in Human Colorectal Adenocarcinoma
Messa, C., Russo, F., Gabriella Caruso, M., & Di Leo, A. (1998) · Acta Oncologica · doi:10.1080/028418698429595 · Cited by 251
Tabernero, J., Van Cutsem, E., Lakomý, R., Prausová, J., Ruff, P., van Hazel, G. A., Moiseyenko, V. M., Ferry, D. R., McKendrick, J. J., Soussan-Lazard, K., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.09.013 · Cited by 242
New platinum antitumor complexes
Kelland, L. R. (1993) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(93)90042-3 · Cited by 237
Molecular determinants of cetuximab efficacy.
Vallböhmer, D., Zhang, W., Gordon, M., Yang, D. Y., Yun, J., Press, O. A., Rhodes, K. E., Sherrod, A. E., Iqbal, S., Danenberg, K. D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.100 · Cited by 234
Porębska, I., Harłozińska, A., & Bojarowski, T. (2000) · Tumor Biology · doi:10.1159/000030116 · Cited by 234
Boyer, J., McLean, E. G., Aroori, S., Wilson, P., McCulla, A., Carey, P. D., Longley, D. B., & Johnston, P. G. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0362 · Cited by 229
Díaz-Rubio, E., Sastre, J., Zaniboni, A., Labianca, R., Cortés-Funes, H., de Braud, F., Boni, C., Benavides, M., Dallavalle, G., & Homerin, M. (1998) · Annals of Oncology · doi:10.1023/a:1008200825886 · Cited by 228
Sohn, K.-J., Croxford, R., Yates, Z., Lucock, M., & Kim, Y.-I. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh015 · Cited by 221
Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
Meijer, C., Mulder, N. H., Timmer‐Bosscha, H., Sluiter, W. J., Meersma, G. J., & de Vries, E. G. E. (1992) · PubMed · Cited by 216
Muro, K., Boku, N., Shimada, Y., Tsuji, A., Sameshima, S., Baba, H., Satoh, T., Denda, T., Ina, K., Nishina, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70181-9 · Cited by 215
DNA mismatch repair genes and colorectal cancer
WHEELER, J. M. D., BODMER, W. F., WHEELER, J. M. D., & MORTENSEN, N. J. M. (2000) · Gut · doi:10.1136/gut.47.1.148 · Cited by 201
Spano, J. P., Fagard, R., Soria, J.-C., Rixe, O., Khayat, D., & Milano, G. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi057 · Cited by 195
Chu, E., & Allegra, C. J. (1993) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4615-2488-5_16 · Cited by 166
Acquired resistance to EGFR‐targeted therapies in colorectal cancer
Van Emburgh, B. O., Sartore-Bianchi, A., Di Nicolantonio, F., Siena, S., & Bardelli, A. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.003 · Cited by 160
The discovery of the placental growth factor and its role in angiogenesis: a historical review
Ribatti, D. (2008) · Angiogenesis · doi:10.1007/s10456-008-9114-4 · Cited by 158
In vitro studies on the mechanisms of oxaliplatin resistance
Hector, S., Bolanowska-Higdon, W., Zdanowicz, J., Hitt, S., & Pendyala, L. (2001) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800100363 · Cited by 154
Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years
Pańczyk, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i29.9775 · Cited by 140
Saridaki, Z., Tzardi, M. N., Papadaki, C., Sfakianaki, M., Pega, F., Kalikaki, A., Tsakalaki, E., Trypaki, M., Messaritakis, I., Stathopoulos, E. N., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015980 · Cited by 138
Soong, R., Shah, N., Salto-Tellez, M., Tai, B. C., Soo, R. A., Han, H. C., Ng, S. S., Tan, W. L., Zeps, N., Joseph, D., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm599 · Cited by 136
Lieu, C. H., Tran, H. T., Jiang, Z.-Q., Mao, M., Overman, M. J., Lin, E. H., Eng, C., Morris, J. S., Ellis, L. M., Heymach, J. V., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077117 · Cited by 136
Hong, Y. S., Park, Y. S., Lim, H. Y., Lee, J., Kim, T. W., Kim, K., Kim, S. Y., Baek, J. Y., Kim, J. H., Lee, K., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70363-7 · Cited by 134
Hobor, S., Emburgh, B. O. V., Crowley, E. H., Misale, S., Nicolantonio, F. D., & Bardelli, A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0774 · Cited by 127
The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells
Fedier, A., Steiner, R. A., Schwarz, V. A., Lenherr, L., Haller, U., & Fink, D. A. (2003) · International Journal of Oncology · doi:10.3892/ijo.22.5.1169 · Cited by 115
Étienne-Grimaldi, M.-C., Milano, G. A., Maindrault‐Gœbel, F., Chibaudel, B., Formento, J., Francoual, M., Lledo, G., André, T., Mabro, M., Mineur, L., et al. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03556.x · Cited by 114
Sood, A., McClain, D., Maitra, R., Basu-Mallick, A., Seetharam, R. N., Kaubisch, A., Rajdev, L. N., Mariadason, J. M., Tanaka, K. E., & Goel, S. (2012) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.12.001 · Cited by 111
Meropol, N. J., Gold, P. J., Diasio, R. B., Andria, M. L., Dhami, M. S., Godfrey, T., Kovatich, A. J., Lund, K. A., Mitchell, E. P., & Schwarting, R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.2084 · Cited by 111
Moutinho, C., Martínez‐Cardús, A., Santos, C., Navarro-Perez, V., Martinez‐Balibrea, E., Musulén, E., Carmona, F. J., Bianchi, A. S., Cassingena, A., Siena, S., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt322 · Cited by 103
Koopman, M., Venderbosch, S., van Tinteren, H., Ligtenberg, M. J. L., Nagtegaal, I. D., van Krieken, J. H., & Punt, C. J. A. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.04.017 · Cited by 101
Longley, D. B., Boyer, J. D., Allen, W. L., Latif, T., Ferguson, P., Maxwell, P. J., McDermott, U., Lynch, M., Harkin, D. P., & Johnston, P. G. (2002) · PubMed · Cited by 100
Qiu, L., Tang, Q., Bai, J., Qian, X., Li, R., Liu, B., & Zheng, M. (2008) · International Journal of Cancer · doi:10.1002/ijc.23822 · Cited by 97
Shirao, K., Hoff, P. M., Ohtsu, A., Loehrer, P. J., Hyodo, I., Wadler, S., Wadleigh, R. G., O'Dwyer, P. J., Muro, K., Yamada, Y., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.017 · Cited by 95
Mésange, P., Poindessous, V., Sabbah, M., Escargueil, A. E., de Gramont, A., & Larsen, A. K. (2014) · Oncotarget · doi:10.18632/oncotarget.1671 · Cited by 95
New Topoisomerase I mutations are associated with resistance to camptothecin
Gongora, C., Vié, N., Tuduri, S., Denis, V., Causse, A., Auzanneau, C., Collod‐Béroud, G., Coquelle, A., Pasero, P., Pourquier, P., et al. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-64 · Cited by 94
Cassidy, J., Saltz, L., Twelves, C., Van Cutsem, E., Hoff, P., Kang, Y., Saini, J. P., Gilberg, F., & Cunningham, D. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr031 · Cited by 90
Marcuello, E., Altés, A., Menoyo, A., del Rı́o, E., & Baiget, M. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0089-1 · Cited by 79
Samuel, S., Fan, F., Dang, L. H., Xia, L., Gaur, P., & Ellis, L. M. (2010) · Oncogene · doi:10.1038/onc.2010.496 · Cited by 72
Isshi, K., Sakuyama, T., Gen, T., Nakamura, Y., Kuroda, T., Katuyama, T., & Maekawa, Y. (2002) · International Journal of Clinical Oncology · doi:10.1007/s101470200051 · Cited by 70
Overcoming Resistance to Antiangiogenic Therapies
Tejpar, S., Prenen, H., & Mazzone, M. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0068 · Cited by 67
Role of uridine phosphorylase in the anabolism of 5-fluorouracil
Schwartz, P. M., Moir, R. D., Cm, H., Turek, P. J., & Handschumacher, R. E. (1985) · Biochemical Pharmacology · doi:10.1016/0006-2952(85)90737-3 · Cited by 66
Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation
Cummings, J., Boyd, G. W., Ethell, B. T., Macpherson, J. S., Burchell, B., Smyth, J. F., & Jodrell, D. I. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00812-7 · Cited by 65
Jürgensmeier, J. M., Schmoll, H., Robertson, J. D., Brooks, L., Taboada, M., Morgan, S. R., Wilson, D. M., & Hoff, P. M. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.79 · Cited by 64
Houghton, J. A., & Houghton, P. J. (1983) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(83)90013-5 · Cited by 62
Tumor resistance to anti-VEGF therapy through up-regulation of VEGF-C expression
Li, D., Xie, K., Ding, G., Li, J., Chen, K., Li, H., Qian, J., Jiang, C., & Fang, J. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.12.004 · Cited by 62
Systems Pharmacology Assessment of the 5-Fluorouracil Pathway
Muhale, F., Wetmore, B. A., Thomas, R. S., & McLeod, H. L. (2011) · Pharmacogenomics · doi:10.2217/pgs.10.188 · Cited by 57
Takebe, N., Zhao, S.-C., Ural, A. U., Johnson, M. R., Banerjee, D., Diasio, R. B., & Bertino, J. R. (2001) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700393 · Cited by 57
Stark, M., Bram, E. E., Akerman, M., Mandel‐Gutfreund, Y., & Assaraf, Y. G. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.163444 · Cited by 56
Esposito, C., Rachiglio, A. M., La Porta, M. L., Sacco, A., Roma, C., Iannaccone, A., Tatangelo, F., Forgione, L., Pasquale, R., Barbaro, A., et al. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.26340 · Cited by 53
A Novel Mechanism of Resistance to Epidermal Growth Factor Receptor Antagonism In vivo
Rajput, A., Koterba, A. P., Kreisberg, J. I., Foster, J. M., Willson, J. K. V., & Brattain, M. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2773 · Cited by 52
Tsurutani, J., Nitta, T., Hirashima, T., Komiya, T., Uejima, H., Tada, H., Negoro, S., Tohda, A., Fukuoka, M., & Nakagawa, K. (2002) · Lung Cancer · doi:10.1016/s0169-5002(01)00425-1 · Cited by 51
Stefano, A. D., & Carlomagno, C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i29.9732 · Cited by 51
Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives
Hohla, F., Winder, T., Greil, R., Rick, F. G., Block, N. L., & Schally, A. V. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i20.6102 · Cited by 46
DPD is a molecular determinant of capecitabine efficacy in colorectal cancer
Vallböhmer, D., Yang, D., Kuramochi, H., Shimizu, D., Danenberg, K. D., Lindebjerg, J., Nielsen, J. S., Jakobsen, A. K. M., & Danenberg, P. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.2.413 · Cited by 44
Kojima, A., Hackett, N. R., & Crystal, R. G. (1998) · PubMed · Cited by 43
Targeted Therapy for Metastatic Colorectal Cancer: Role of Aflibercept
Mitchell, E. P. (2012) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2012.08.001 · Cited by 43
Baba, H., Watanabe, M., Okabe, H., Miyamoto, Y., Sakamoto, Y., Baba, Y., Iwatsuki, M., Chikamoto, A., & Beppu, T. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.502 · Cited by 43
Wang, H., Bian, T., Liu, D., Jin, T., Chen, Y., Lin, A., & Chen, C. (2011) · Pharmacogenomics · doi:10.2217/pgs.10.202 · Cited by 38
Zhao, J., Li, W., Zhu, D., Yu, Q., Zhang, Z., Sun, M., Cai, S., & Zhang, W. (2013) · Medical Oncology · doi:10.1007/s12032-013-0802-6 · Cited by 37
Ciardiello, F., & Normanno, N. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0261 · Cited by 36 · cited 1×
“2011; Ciardiello and Normanno, 2011; Bertotti et al.”
Yanagisawa, Y., Maruta, F., Iinuma, N., Ishizone, S., Koide, N., Nakayama, J., & Miyagawa, S. (2006) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520600994418 · Cited by 31
Kim, S. Y., Hong, Y. S., Shim, E., Kong, S.-Y., Shin, A., Baek, J. Y., & Jung, K. H. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.479 · Cited by 28
Hirschi, B., Gallmeier, E., Ziesch, A., Marschall, M. K., & Kolligs, F. T. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-122 · Cited by 27
Smith, D. H., Christensen, I. J., Jensen, N. F., Markussen, B., Rømer, M. U., Nygård, S. B., Müller, S., Nielsen, H. J., Brünner, N., & Nielsen, K. V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060613 · Cited by 23
Lindskog, E. B., Derwinger, K., Gustavsson, B., Falk, P., & Wettergren, Y. (2014) · BMC Clinical Pathology · doi:10.1186/1472-6890-14-25 · Cited by 22
The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies
Meriggi, F. A., Vermi, W., Bertocchi, P., & Zaniboni, A. (2014) · Reviews on Recent Clinical Trials · doi:10.2174/1568026614666140423121525 · Cited by 20
Vallböhmer, D., Kuramochi, H., Shimizu, D., Danenberg, K. D., Lindebjerg, J., Nielsen, J., Jakobsen, A. K. M., & Danenberg, P. V. (2006) · International Journal of Oncology · doi:10.3892/ijo.28.2.527 · Cited by 19
Petrioli, R., Bargagli, G., Lazzi, S., Pascucci, A., Francini, E., Bellan, C., Conca, R., Martellucci, I., Fiaschi, A. I., Lorenzi, B., et al. (2010) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328334d88a · Cited by 19
Chemotherapy for colorectal cancer
Nicum, S., Midgley, R. S., & Kerr, R. S. (2000) · Journal of the Royal Society of Medicine · doi:10.1177/014107680009300807 · Cited by 17
Choi, Y. H., Kim, T. W., Kim, K., Lee, S. S., Hong, Y. S., Ryu, M., Lee, J., Chang, H. M., Ryoo, B., Kim, H.-S., et al. (2012) · Oncology · doi:10.1159/000337989 · Cited by 16
Price, T. J., Newhall, K. J., Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. V., Thomas, A., Tjulandin, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.3_suppl.740 · Cited by 15
Cao, C., Zhang, X., Kuang, M., Gu, D., He, M., Chen, J., & Tang, C. (2014) · Cancer Science · doi:10.1111/cas.12465 · Cited by 12
Dianjun, Y., & Zhang, J. (2013) · Europe PMC (PubMed Central) · doi:10.7497/j.issn.2095-3941.2013.01.002 · Cited by 10
Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer
Cubillo, A., Rodríguez-Pascual, J., López‐Ríos, F., Plaza, C., García, E., Álvarez-Gallego, R., Vicente, E., Quijano, Y., Hernando, O., Rubio, C., et al. (2014) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000045 · Cited by 9
Cited by
5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Vodenkova, S., Buchler, T., Cervena, K., Veskrnova, V., Vodicka, P., & Vymetalkova, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107447 · Cited by 956
Sethy, C., & Kundu, C. N. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111285 · Cited by 539
Noncoding RNAs in gastric cancer: implications for drug resistance
Wei, L., Sun, J., Zhang, N., Zheng, Y., Wang, X., Lv, L., Liu, J., Xu, Y., Shen, Y., & Yang, M. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01185-7 · Cited by 468
Biomarker-guided therapy for colorectal cancer: strength in complexity
Sveen, A., Kopetz, S., & Lothe, R. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0241-1 · Cited by 320
Heat Shock Proteins: Agents of Cancer Development and Therapeutic Targets in Anti-Cancer Therapy
Yun, C. W., Kim, H. J., Lim, J. H., & Lee, S. H. (2019) · Cells · doi:10.3390/cells9010060 · Cited by 284
Metadata
- Authors
- Hammond, W. A., Swaika, A., & Mody, K.
- Venue
- Therapeutic Advances in Medical Oncology
- Publisher
- SAGE Publications
- Published
- 2015-12-18
- Volume
- 8
- Issue
- 1
- Pages
- 57-84
- ISSN
- 1758-8340 (ISSN-L)
- 1758-8359
- OpenAlex
- W2274106006
- Cited by
- 519
- References
- 185
- FWCI
- 10.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.